Ticker > Company >

Aarey Drugs & Pharma share price

Aarey Drugs & Pharmaceuticals Ltd.

NSE: AAREYDRUGS BSE: 524412 SECTOR: Pharmaceuticals & Drugs  30.2 K   31   7

74.00
+1.58 (2.18%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 75.45

Today's Low

₹ 72

52 Week High

₹ 74.49

52 Week Low

₹ 31.3

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

209.82 Cr.

Enterprise Value

239.58 Cr.

No. of Shares

2.84 Cr.

P/E

50.5

P/B

1.53

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  48.4

CASH

1.59 Cr.

DEBT

31.35 Cr.

Promoter Holding

44.8 %

EPS (TTM)

₹  1.47

Sales Growth

-5.57%

ROE

3.82 %

ROCE

6.09%

Profit Growth

24.2 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-5.57%
3 Year4.33%
5 Year2.21%

Profit Growth

1 Year24.2%
3 Year-10.41%
5 Year-6.46%

ROE%

1 Year3.82%
3 Year4.49%
5 Year5.42%

ROCE %

1 Year6.09%
3 Year7.41%
5 Year8.03%

Debt/Equity

0.2406

Price to Cash Flow

-70.09

Interest Cover Ratio

2.2212

CFO/PAT (5 Yr. Avg.)

0.166857964414687

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 44.80 0.00
Mar 2025 44.80 0.00
Dec 2024 44.80 0.00
Sep 2024 45.44 0.00
Jun 2024 45.28 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 77.3397 days.

 Limitations

  • The company has shown a poor profit growth of -10.4139671812615% for the Past 3 years.
  • The company has shown a poor revenue growth of 4.32592834050387% for the Past 3 years.
  • Company has a poor ROE of 4.48500061801246% over the past 3 years.
  • Company has negative cash flow from operations of -2.9938.
  • Tax rate is low at 12.3379.
  • The company has a low EBITDA margin of 1.53853167098449% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 126.91 105.14 133.79 108.1 102.21
Total Expenditure 125.73 101.42 131.59 112.3 100.51
Operating Profit 1.18 3.73 2.2 -4.21 1.7
Other Income 1.58 0.02 0.68 7.54 1.55
Interest 0.96 1.51 0.9 3.13 1.04
Depreciation 0.47 0.49 0.58 -1.42 0.49
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.33 1.75 1.4 1.63 1.73
Tax 0.09 0.15 0.68 1.16 0.36
Profit After Tax 1.24 1.6 0.72 0.47 1.37
Adjusted EPS (Rs) 0.44 0.57 0.26 0.17 0.48

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 300.09 348.42 492.76 418.96 395.62
Total Expenditure 296.86 343.77 481.37 411.23 391.17
Operating Profit 3.23 4.65 11.4 7.72 4.45
Other Income 6.69 7.01 2.67 2.73 6.96
Interest 1.79 2.44 2.04 2.87 4.38
Depreciation 0.89 0.92 1.99 1.57 1.7
Exceptional Items 0 0 0 0 0
Profit Before Tax 7.24 8.3 10.04 6.01 5.34
Tax 1.45 1.79 3.48 2.24 0.66
Net Profit 5.79 6.51 6.55 3.77 4.68
Adjusted EPS (Rs.) 2.48 2.79 2.58 1.49 1.67

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 23.38 23.38 25.38 25.38 28.05
Total Reserves 68.96 75.48 88.25 92.02 104.72
Borrowings 0.02 0 3.34 4.36 3.22
Other N/C liabilities 1.44 3.37 1.46 1.42 0.75
Current liabilities 100.28 130.8 126.74 168.14 166.55
Total Liabilities 194.08 233.04 245.17 291.32 303.29
Assets
Net Block 12.3 14.26 14.47 13.94 12.96
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.44 0.4 0.4 0.4 1.38
Loans & Advances 0 0 9.09 6.37 6.36
Other N/C Assets 0 0 2.4 0.01 0.01
Current Assets 181.34 218.38 218.82 270.61 282.59
Total Assets 194.08 233.04 245.17 291.32 303.29
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 7.24 8.3 10.03 6.01 5.34
Adjustment 2.68 3.35 3.99 4.44 5.41
Changes in Assets & Liabilities -5.56 -4.51 -9.93 -9.45 -12.42
Tax Paid -1.5 -1.66 -3.59 -2.28 -1.33
Operating Cash Flow 2.86 5.48 0.5 -1.28 -2.99
Investing Cash Flow -0.92 -2.88 -3.21 0.44 -1.7
Financing Cash Flow -1.8 -2.45 2.25 1.35 5.58
Net Cash Flow 0.13 0.15 -0.46 0.51 0.89

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 45.28 45.44 44.80 44.80 44.80
bina rajesh ghatalia 14.27 14.32 14.12 14.12 14.12
mihir rajesh ghatalia 10.11 10.14 10.00 10.00 10.00
mira mihir ghatalia 2.46 2.47 2.43 2.43 2.43
nimit impex 7.16 7.19 7.09 7.09 7.09
nimit rajesh ghatalia 4.10 4.11 4.06 4.06 4.06
rajesh pranlal ghatalia 0.01 0.01 0.01 0.01 0.01
suraj tradelinks 7.16 7.19 7.09 7.09 7.09
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 54.72 54.56 55.20 55.20 55.20
archana pramod wani - - - 1.41 1.41
chetan kiritbhai mehta 1.60 1.07 1.59 1.59 1.59
india opportunities growt... 3.40 2.67 2.34 - 1.73
krishnamurthy c g - - - 1.73 1.73
llp 0.14 0.22 0.21 - 0.17
vijaykumar babulal shah - - 1.06 1.06 1.06
black hawk properties pri... - - - 1.34 -
india opportunities growt... - - - 2.34 -
zil penil doshi 1.34 1.34 1.32 1.32 -
c g krishnamurthy 1.75 1.75 1.73 - -
black hawk properties pvt... 1.35 - - - -
vijaykumar b shah 1.07 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ACUITE
Credit SMERA
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

 No Latest News available for this company.Report us

Aarey Drugs & Pharma Stock Price Analysis and Quick Research Report. Is Aarey Drugs & Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Aarey Drugs & Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Aarey Drugs & Pharma has a PE ratio of 50.0955370547291 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Aarey Drugs & Pharma has ROA of 1.5754% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Aarey Drugs & Pharma has a Current ratio of 1.6967.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Aarey Drugs & Pharma has a ROE of 3.8172%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Aarey Drugs & Pharma has a Debt to Equity ratio of 0.2406 which means that the company has low proportion of debt in its capital.

  • Sales growth: Aarey Drugs & Pharma has reported revenue growth of -5.5706% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Aarey Drugs & Pharma for the current financial year is 1.12515131393195%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Aarey Drugs & Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Aarey Drugs & Pharma is Rs 1.4654. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Aarey Drugs & Pharma in Ticker for free. Also, one can get the intrinsic value of Aarey Drugs & Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Aarey Drugs & Pharma FAQs

Q1. What is Aarey Drugs & Pharma share price today?
Ans: The current share price of Aarey Drugs & Pharma is Rs 73.41.

Q2. What is the market capitalisation of Aarey Drugs & Pharma?
Ans: Aarey Drugs & Pharma has a market capitalisation of Rs 208.148938323 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Aarey Drugs & Pharma?
Ans: The PE ratio of Aarey Drugs & Pharma is 50.0955370547291 and the P/B ratio of Aarey Drugs & Pharma is 1.5167198685964, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Aarey Drugs & Pharma share?
Ans: The 52-week high share price of Aarey Drugs & Pharma is Rs 74.5, and the 52-week low share price of Aarey Drugs & Pharma is Rs 31.35.

Q5. Does Aarey Drugs & Pharma pay dividends?
Ans: Currently, Aarey Drugs & Pharma does not pay dividends. Dividend yield of Aarey Drugs & Pharma is around 0%.

Q6. What are the face value and book value of Aarey Drugs & Pharma shares?
Ans: The face value of Aarey Drugs & Pharma shares is Rs 10, while the book value per share of Aarey Drugs & Pharma is around Rs 48.4005. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Aarey Drugs & Pharma?
Ans: Aarey Drugs & Pharma has a total debt of Rs 31.3523 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Aarey Drugs & Pharma?
Ans: The ROE of Aarey Drugs & Pharma is 3.8172% and ROCE of Aarey Drugs & Pharma is 6.0881%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Aarey Drugs & Pharma a good buy for the long term?
Ans: The Aarey Drugs & Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Aarey Drugs & Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Aarey Drugs & Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Aarey Drugs & Pharma’s financials?
Ans: You can review Aarey Drugs & Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Aarey Drugs & Pharma
X